why choose us

First received: October 16, 2023

Clinical Trial: Spesolimab in Pyoderma Gangrenosum

Study Status: Completed

Recruit Status: RECRUITING

Condition: Pyoderma Gangrenosum

Study Type: INTERVENTIONAL


Official Title: Characterizing Pyoderma Gangrenosum Lesion Regression and Remission by IL-36 Receptor Targeting With Spesolimab

Brief Summary: The purpose of this research study is to assess the feasibility of using spesolimab in participants with moderate to severe pyoderma ganrenosum.Pyoderma gangrenosum is a rare, inflammatory, autoimmune condition which results in ulceration of skin.The study will also investigate the body's immune response to the spesolimab (when the body detects and defends itself against substances that appear unknown and harmful).

Read more